- Home
- ADPT vs AGIO Comparison
ADPT vs AGIO Comparison
Compare ADPT & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- AGIO
- Stock Information
- Founded
- ADPT 2009
- AGIO 2007
- Country
- ADPT United States
- AGIO United States
- Employees
- ADPT N/A
- AGIO N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- ADPT Health Care
- AGIO Health Care
- Exchange
- ADPT Nasdaq
- AGIO Nasdaq
- Market Cap
- ADPT 2.6B
- AGIO 2.4B
- IPO Year
- ADPT 2019
- AGIO 2013
- Fundamental
- Price
- ADPT $16.88
- AGIO $39.98
- Analyst Decision
- ADPT Strong Buy
- AGIO Strong Buy
- Analyst Count
- ADPT 10
- AGIO 4
- Target Price
- ADPT $15.10
- AGIO $59.33
- AVG Volume (30 Days)
- ADPT 1.5M
- AGIO 561.3K
- Earning Date
- ADPT 11-05-2025
- AGIO 10-30-2025
- Dividend Yield
- ADPT N/A
- AGIO N/A
- EPS Growth
- ADPT N/A
- AGIO N/A
- EPS
- ADPT N/A
- AGIO N/A
- Revenue
- ADPT $205,216,000.00
- AGIO $44,791,000.00
- Revenue This Year
- ADPT $34.41
- AGIO $23.74
- Revenue Next Year
- ADPT $14.03
- AGIO $159.90
- P/E Ratio
- ADPT N/A
- AGIO N/A
- Revenue Growth
- ADPT 21.60
- AGIO 36.26
- 52 Week Low
- ADPT $4.27
- AGIO $23.42
- 52 Week High
- ADPT $17.89
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- ADPT 59.44
- AGIO 43.69
- Support Level
- ADPT $16.59
- AGIO $40.18
- Resistance Level
- ADPT $17.76
- AGIO $44.10
- Average True Range (ATR)
- ADPT 0.77
- AGIO 1.80
- MACD
- ADPT -0.09
- AGIO -0.39
- Stochastic Oscillator
- ADPT 50.12
- AGIO 16.92
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.